Product for screening and evaluating benign lung diseases based on saliva specific glycoprotein sugar chain structure and application

Abstract

The invention discloses a lung benign disease (COPD) related screening and evaluation product based on a saliva specific glycoprotein sugar chain structure and an application. Products for lung benigndisease screening, early diagnosis, risk assessment, drug screening and / or curative effect assessment are provided for saliva samples. According to the product, change of expression levels of specific glycoprotein sugar chain structures (4GlcNAc, Sia [alpha] 2-3Gal, Gal [beta] 1-3GlcNAc, Sia [alpha] 2-3) in a saliva sample is detected, and whether 10 specific N-sugar chains are contained is detected, correspondingly, lectin playing a role in specific binding recognition is MAL-I and can be independently used as a reagent for recognizing a saliva specific glycoprotein sugar chain structure tobe used for preparing related medical products.

Description

technical field [0001] The invention relates to the determination of benign pulmonary disease (COPD) markers based on salivary specific glycoprotein and related products and applications. Background technique [0002] Primary bronchial lung cancer, referred to as lung cancer, is a malignant tumor originating from the bronchial mucosa or glands. Lung cancer is the most common cause of death from malignant tumors worldwide. Moreover, its incidence is increasing year by year at a rate of about 5%. It is estimated that by 2020, the number of deaths due to lung cancer will reach 50% of the total number of deaths caused by malignant tumors. Lung cancer has become a major health and social problem that needs to be solved urgently in various countries around the world, especially in developing countries. A nationwide sampling survey conducted in 2010 showed that the mortality rate of lung cancer had risen to 30.83 / 100,000, of which 41.34 / 100,000 were males and 19.84 / 100,000 female...

AI Technical Summary

Problems solved by technology

[0004] Although great progress has been made in the treatment of lung cancer in recent years, overall, the prognosis of lung cancer is still very unsatisfactory. The 5-year survival rates of non-small cell lung cancer and small cell lung cancer are only 14% and 4%, respectively. %

The main reason for this situation is that the onset of lung cancer is hidden, and there are usually no obvious symptoms in the early stage. Most lung cancer patients are already in the advanced stage when they are diagnosed, and they lose the chance of surgical cure.

Images